Skip to main content

Akava Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for the Treatment of Amyotrophic Lateral Sclerosis

August 22, 2023

Prof. Richard Silverman's pioneering biopharmaceutical company, Akava Therapeutics, Inc., had its compound AKV9 given FDA clearance. This cell-based and mechanism-focused drug tackles the degeneration of the neuron. Phase I trials of AKV9 can now begin in healthy human subjects to evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses.

Continue Reading